Compare Procter & Gamble Health with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs ALEMBIC PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH ALEMBIC PHARMA PROCTER & GAMBLE HEALTH/
ALEMBIC PHARMA
 
P/E (TTM) x 52.7 16.3 323.6% View Chart
P/BV x 4.8 3.7 127.3% View Chart
Dividend Yield % 10.0 1.0 977.1%  

Financials

 PROCTER & GAMBLE HEALTH   ALEMBIC PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
ALEMBIC PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs3,549664 534.5%   
Low Rs1,301412 315.5%   
Sales per share (Unadj.) Rs511.4208.7 245.0%  
Earnings per share (Unadj.) Rs61.331.0 197.7%  
Cash flow per share (Unadj.) Rs74.037.1 199.4%  
Dividends per share (Unadj.) Rs440.005.50 8,000.0%  
Dividend yield (eoy) %18.11.0 1,775.4%  
Book value per share (Unadj.) Rs927.8144.2 643.3%  
Shares outstanding (eoy) m16.60188.52 8.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.6 183.9%   
Avg P/E ratio x39.617.4 227.9%  
P/CF ratio (eoy) x32.814.5 225.9%  
Price / Book Value ratio x2.63.7 70.0%  
Dividend payout %717.917.7 4,046.1%   
Avg Mkt Cap Rs m40,257101,461 39.7%   
No. of employees `0001.1NA-   
Total wages/salary Rs m1,3137,467 17.6%   
Avg. sales/employee Rs Th7,486.7NM-  
Avg. wages/employee Rs Th1,157.6NM-  
Avg. net profit/employee Rs Th897.2NM-  
INCOME DATA
Net Sales Rs m8,49039,347 21.6%  
Other income Rs m24494 260.0%   
Total revenues Rs m8,73439,441 22.1%   
Gross profit Rs m1,4828,736 17.0%  
Depreciation Rs m2111,152 18.3%   
Interest Rs m0184 0.0%   
Profit before tax Rs m1,5147,493 20.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,568 35.9%   
Profit after tax Rs m1,0175,844 17.4%  
Gross profit margin %17.522.2 78.6%  
Effective tax rate %37.120.9 177.6%   
Net profit margin %12.014.9 80.7%  
BALANCE SHEET DATA
Current assets Rs m15,34319,577 78.4%   
Current liabilities Rs m1,96014,896 13.2%   
Net working cap to sales %157.611.9 1,325.0%  
Current ratio x7.81.3 595.6%  
Inventory Days Days4990 54.3%  
Debtors Days Days2845 62.7%  
Net fixed assets Rs m1,20927,097 4.5%   
Share capital Rs m166377 44.0%   
"Free" reserves Rs m15,23526,811 56.8%   
Net worth Rs m15,40127,188 56.6%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m17,59547,778 36.8%  
Interest coverage xNM41.7-  
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.50.8 58.6%   
Return on assets %5.812.6 45.8%  
Return on equity %6.621.5 30.7%  
Return on capital %10.323.6 43.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63619,453 8.4%   
Fx outflow Rs m4,3686,065 72.0%   
Net fx Rs m-2,73213,388 -20.4%   
CASH FLOW
From Operations Rs m-1,3048,120 -16.1%  
From Investments Rs m12,697-7,556 -168.0%  
From Financial Activity Rs m-301590 -50.9%  
Net Cashflow Rs m11,0931,153 961.8%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 2.9 627.6%  
FIIs % 1.0 9.1 11.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 13.9 209.4%  
Shareholders   28,591 49,328 58.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 18, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS